Abington, Pennsylvania Clinical Trials

A listing of Abington, Pennsylvania clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 48 clinical trials
A Study Evaluating The Safety Tolerability Pharmacokinetics And Efficacy Of Venetoclax In Combination With Atezolizumab Carboplatin And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.

colony stimulating factor
measurable disease
cns metastases
serum pregnancy test
atezolizumab
Fox Chase Cancer Center
 (4.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +15 other locations
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the …

soft tissue lesion
bone lesion
gonadotropin releasing hormone
fatigue
luteinizing hormone-releasing hormone agonist
Research Site
 (4.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +106 other locations
A Study Evaluating The Safety Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen Receptor)-targeted therapy. The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort …

castration-resistant prostate cancer
hair thinning
bone lesion
luteinizing hormone
gonadotropin releasing hormone
Fox Chase Cancer Center
 (4.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +17 other locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

cancer metastatic
endocrine therapy
estrogen receptor
breast cancer
oestrogen receptor positive breast cancer
Investigational Site Number 8400001
 (7.6 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +125 other locations
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease  

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

dopamine
bradykinesia
dopamine transporter
early parkinson's
resting tremor
Abington Neurological Associates Willow Grove
 (1.9 away)
  • 0 views
  • 28 Jun, 2022
  • +125 other locations
Test reports v6.12 (DO NOT VISIT)

Test

Abington Neurological Associates Willow Grove
 (1.9 away) Contact site
  • 0 views
  • 02 Mar, 2026
  • +2 other locations
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate …

covid-19
blood test
Temple Univ School of Med
 (7.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +10 other locations
Phase I Study in Advanced Malignancies

RDT aims to take advantage of the relatively safer toxicity profiles of both lower dose radiation therapy and systemic ALA to treat non-superficial lesions in a manner similar to photodynamic therapy. The doses of radiation administered in this study will be lower than those typically used to treat cancer. However, …

serum total bilirubin level
growth factor
mitomycin
alopecia
hair thinning
Fox Chase Cancer Center
 (4.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.

covid-19
SARS
oximetry
acalabrutinib
pneumonia
Research Site
 (7.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +9 other locations
A Study of LY3819253 (LY-CoV555) in Participants With Mild to Moderate COVID-19 Illness

The purpose of this study is to measure how well LY3819253 works against the virus that causes COVID-19. LY3819253 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus …

headache
respiratory disorder
sore throat
body mass index
intermittent positive pressure ventilation
Temple University Hospital
 (7.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +61 other locations